Successful use of letrozole in male breast cancer: A case report and review of hormonal therapy for male breast cancer

被引：45

作者：

Zabolotny, BP ^{[1
]}

Zalai, CV ^{[1
]}

Meterissian, SH ^{[1
]}

机构：

[1] McGill Univ, Ctr Hlth, Royal Victoria Hosp, Div Surg Oncol, Montreal, PQ H3A 1A1, Canada

来源：

JOURNAL OF SURGICAL ONCOLOGY | 2005年 / 90卷 / 01期

关键词：

male breast neoplasms; aromatase inhibitors;

D O I：

10.1002/jso.20233

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Male breast cancer is an uncommon occurrence. Treatment of male breast cancer is typically extrapolated from data on the treatment of female breast cancer. Recently, aromatase inhibition has been proven as an effective therapy for female breast cancer, particularly in the setting of advanced cancers. The efficacy of aromatase inhibitors in males, however, has not been established. We report the successful treatment of a male with locally advanced breast cancer using the aromatase inhibitor letrozole. (c) 2005 Wiley-Liss, Inc.

引用

页码：26 / 30

页数：5

共 38 条

[1] ADJUVANT CHEMOTHERAPY IN MALES WITH CANCER OF THE BREAST [J].

BAGLEY, CS ;

WESLEY, MN ;

YOUNG, RC ;

LIPPMAN, ME .

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1987, 10 (01) :55-60

[2]

Baum M, 2002, LANCET, V359, P2131

[3] Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women:: Results of the tamoxifen or arimidex randomized group efficacy and tolerability study [J].

Bonneterre, J ;

Thürlimann, B ;

Robertson, JFR ;

Krzakowski, M ;

Mauriac, L ;

Koralewski, P ;

Vergote, I ;

Webster, A ;

Steinberg, M ;

von Euler, M .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (22) :3748-3757

[4]

*CAN CANC SURV, 1999, CANC BREAST MAL ALL

[5]

Donegan WL, 1998, CANCER-AM CANCER SOC, V83, P498, DOI 10.1002/(SICI)1097-0142(19980801)83:3<498::AID-CNCR19>3.0.CO

[6]

2-R

[7] Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study [J].

Eiermann, W ;

Paepke, S ;

Appfelstaedt, J ;

Llombart-Cussac, A ;

Eremin, J ;

Vinholes, J ;

Mauriac, L ;

Ellis, M ;

Lassus, M ;

Chaudri-Ross, HA ;

Dugan, M ;

Borgs, M ;

Semiglazov, V .

ANNALS OF ONCOLOGY, 2001, 12 (11) :1527-1532

[8] Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer:: Evidence from a phase III randomized trial [J].

Ellis, MJ ;

Coop, A ;

Singh, B ;

Mauriac, L ;

Llombert-Cussac, A ;

Jänicke, F ;

Miller, WR ;

Evans, DB ;

Dugan, M ;

Brady, C ;

Quebe-Fehling, E ;

Borgs, M .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (18) :3808-3816

[9]

FARROW JOSEPH H., 1942, SCIENCE, V95, P654, DOI 10.1126/science.95.2478.654

[10] Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study [J].

Geisler, J ;

Haynes, B ;

Anker, G ;

Dowsett, M ;

Lonning, PE .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (03) :751-757

← 1 2 3 4 →